ENSPRYNG 120MG/ML
SATRALIZUMAB
What it does
Satralizumab is a medication used to treat certain autoimmune conditions by targeting specific parts of the immune system.
Commonly used for: neuromyelitis optica spectrum disorder (NMOSD), autoimmune diseases
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Food and Drugs Authority · fetched 2026-04-18 08:33:01 · updated 2026-05-29 03:52:24
About this medicine
Satralizumab is a medication used to treat certain autoimmune conditions by targeting specific parts of the immune system.
What it treats
- neuromyelitis optica spectrum disorder (NMOSD)
- autoimmune diseases
How it works
It works by blocking a protein that plays a key role in the immune response, helping to reduce inflammation and prevent damage to nerve cells.
Who it's for
This medication is for adults with specific autoimmune conditions, particularly NMOSD.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: satralizumab
Satralizumab is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R). It is primarily used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a condition characterized by inflammation of the optic nerves and spinal cord. By inhibiting IL-6R, satralizumab plays a crucial role in modulating immune responses associated with this autoimmune disorder.
Indications
- Neuromyelitis optica spectrum disorder (NMOSD)
- Recurrent neuromyelitis optica attacks
Dosage
Children: Refer to product-specific guidelines for dosing.
Adults: Refer to product-specific guidelines for dosing.
Mechanism of action
Satralizumab binds to the soluble and membrane-bound forms of the interleukin-6 receptor, preventing the binding of interleukin-6 (IL-6) to its receptor. This inhibition disrupts IL-6 mediated signaling pathways that are involved in the inflammatory process, thereby reducing inflammation and autoimmunity associated with NMOSD.
Pharmacodynamics
The pharmacodynamics of satralizumab involve the modulation of the immune system through the inhibition of IL-6 signaling. IL-6 is a pro-inflammatory cytokine that plays a significant role in the pathogenesis of various autoimmune diseases. By blocking IL-6R, satralizumab decreases the levels of inflammatory mediators and reduces the activation of immune cells, resulting in decreased disease activity and improved clinical outcomes in patients with NMOSD.
Pharmacokinetics
Satralizumab exhibits a half-life of approximately 23 days, allowing for less frequent dosing. It is administered via subcutaneous injection, with peak plasma concentrations typically reached within 3 to 7 days post-administration. The drug is predominantly eliminated via the reticuloendothelial system, with no significant renal or hepatic metabolism reported.
Contra-indications
- Hypersensitivity to satralizumab or any of its components
- Active infections
Adverse effects
- Injection site reactions
- Headache
- Nausea
- Fatigue
- Increased risk of infections
Interactions
- Immunosuppressants may increase the risk of infections
- Live vaccines should be avoided during treatment
Precautions
- Monitor for signs of infection during treatment
- Use with caution in patients with a history of recurrent infections
- Evaluate for tuberculosis prior to initiation
Pregnancy
Limited data available. Use only if clearly needed, considering potential risks and benefits.
Breast-feeding
Lactation safety not established. Caution is advised, considering potential effects on the infant.
Storage
Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light.
Formulations
- Injectable solution for subcutaneous use
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.